NCT05904379 - AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

233

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

April 15, 2025

Study Completion Date

January 31, 2027

Conditions

Advanced Non-small-cell Lung Cancer

Interventions

DRUG

AK112

Subjects receive AK112 intravenously.

DRUG

AK104

Subjects receive AK104 intravenously.

DRUG

Carboplatin

Subjects receive carboplatin intravenously.

DRUG

paclitaxel

Subjects receive paclitaxel intravenously.

DRUG

pemetrexed

Subjects receive pemetrexed intravenously.

DRUG

Docetaxel

Subjects receive docetaxel intravenously.

Trial Locations (2)

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

RECRUITING

Shanghai Pulmonary Hospital, Shanghai